Test Price
2,800 AED✅ Home Collection Available
CDKN2B / MEN1 Genetic Screening (Multiple Endocrine Neoplasia Type 1) – Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines
تحليل جين CDKN2B/MEN1 للكشف عن أورام الغدد الصماء المتعددة النوع الأول في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
Clinical Grade Accuracy: 99.9% diagnostic sensitivity for CDKN2B and MEN1 variants through ISO 9001:2015-certified (Cert: INT/EGQ/2509DA/3139) next-generation sequencing. Strict adherence to Federal Decree-Law No. 41 of 2024 (Art. 87), UAE PDPL, and CDS Law 2026 for minors.
Premium Logistics: Paid hospital-grade home collection by DHA-licensed phlebotomists (8 AM – 11 PM) using ISO-certified cold-chain transport. VIP mobile service available.
Clinical Guidance: Complimentary telephonic post-test result interpretation by an oncogenetic counselor, aligning genetic findings with your family history and future risk management.
Insurance & Billing: Direct insurance verification via WhatsApp at +971 54 548 8731. Pre-approval assistance provided.
ملخص تنفيذي: اختبار الحمض النووي بتقنية التسلسل من الجيل التالي لجينات CDKN2B وMEN1، يقدم دقة تشخيصية بنسبة 99.9% مع استشارة وراثية مجانية وتجميع منزلي مرخص من هيئة الصحة بدبي، متوافق تماماً مع قانون المرسوم الاتحادي رقم 41 لسنة 2024 وقانون حماية البيانات الشخصية.
Clinical Overview
The CDKN2B / MEN1 NGS panel simultaneously evaluates multiple endocrine neoplasia type 1 (MEN1) tumor suppressor genes and the CDKN2B (p15) cell-cycle regulator, providing a comprehensive hereditary cancer risk profile. This test identifies pathogenic variants in genes linked to endocrine tumors, pancreatic neuroendocrine cancers, and familial melanoma syndromes, enabling precise surveillance or prophylactic interventions.
يقدم هذا الفحص الشامل للجينات CDKN2B وMEN1 تقييماً دقيقاً للاستعداد الوراثي للإصابة بأورام الغدد الصماء المتعددة وسرطانات البنكرياس، معتمداً على أحدث تقنيات التسلسل الجيني.
| Feature | Our Test (CDKN2B/MEN1 NGS Panel) | Closest Alternative (Single-Gene Sequencing) |
|---|---|---|
| Methodology | Next-Generation Sequencing (full gene coverage, CNV detection) | Sanger sequencing (limited to known hotspots) |
| Turnaround Time | 3–4 weeks | 4–6 weeks |
| Variant Coverage | All exons ±20bp intronic boundaries, large deletions/duplications | Selected exons only, no CNV |
| Clinical Utility | MEN1 syndrome, familial atypical multiple mole melanoma, pancreatic cancer risk | Limited to MEN1 or CDKN2B alone |
Physician Insight & Safety Protocol
“As a clinical geneticist, I emphasize that a positive CDKN2B or MEN1 variant must be correlated with detailed family history and biochemical screening. Genetic results are not a stand-alone diagnosis but a powerful tool for preventive care. Always discuss any medication changes with your treating physician.” – Dr. PRABHAKAR REDDY, DHA License No. 61713011
⚠️ Medication Safety Warning: Do not discontinue any prescribed medication, including hormone replacement or antidepressants, before genetic testing without consulting your doctor.
Exclusion Criteria & Emergency Red Flags
- Active chemotherapy or radiotherapy within the last 2 weeks (may affect DNA integrity).
- Known bone marrow failure syndromes with less than 5% circulating leukocytes – insufficient DNA yield.
- If you experience sudden severe abdominal pain, heart palpitations, or uncontrolled hypertension, seek emergency medical care; do not wait for genetic results.
- Specimens must not be frozen; use only provided FTA card or EDTA whole blood at 4°C.
Patient FAQ & Clinical Guidance
1. What does a CDKN2B/MEN1 genetic test tell me, and why do I need a genetic counselling session before it?
The test identifies inherited mutations in CDKN2B and MEN1 genes that significantly elevate lifetime risk for endocrine tumours and melanoma; pre-test counselling constructs a family pedigree to interpret results accurately and tailor screening.
يكشف الاختبار عن طفرات جينية تزيد بشكل كبير من مخاطر أورام الغدد الصماء والورم الميلانيني، وتساعد الاستشارة الوراثية قبل الفحص على رسم شجرة العائلة لتفسير النتائج بدقة.
2. How accurate is the NGS method for CDKN2B/MEN1, and do you report variants of uncertain significance?
With 99.9% analytical sensitivity, the NGS platform detects single nucleotide variants, small indels, and copy number changes; all variants are classified per ACMG guidelines, and VUS are reported with follow-up recommendations.
بدقة تحليلية تصل إلى 99.9%، يكتشف الفحص التغيرات النوكليوتيدية والتعددات النسخية، وتُصنف جميع المتغيرات وفق معايير الكلية الأمريكية لعلم الوراثة الطبية مع توصيات المتابعة.
3. Can I use FTA card blood sample, and how does home collection work in the UAE?
Yes, a single drop of blood on an FTA card is stable at ambient temperature; our DHA-licensed phlebotomist arrives at your doorstep within booking hours and ensures cold-chain transport for extracted DNA or whole blood options.
نعم، يمكن استخدام بطاقة FTA بقطرة دم واحدة؛ يصل الممرض المرخص من هيئة الصحة بدبي إلى منزلك لسحب العينة ونقلها بسلسلة تبريد معتمدة.
Pre- Requirement: Compulsory genetic counselling session to document a comprehensive family pedigree for CDKN2B/MEN1-related conditions. Provide full clinical history, including any prior endocrine tumor diagnoses, melanoma, or pancreatic cancer in family members. No fasting required. FTA card samples must be kept dry and away from direct heat.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians